ORTIN LABORATORIES LIMITED, a Trusted Reliance for Quality
established in the year 1986 to offer QUALITY Drugs and Medicines to the
suffering mankind. Ortin's Formulations unit is located in a spacious area
of 25000 sq feet with all ultra-modern infrastructures as per the WHO
GMP Standards to manufacture the complete range of Pharmaceutical
Formulations of TABLETS, CAPSULES, SYRUPS, and DRY POWDERS. The Company
shares are presently traded in the Madras & Mumbai Stock Exchanges.
In the year 2010, M/s Vineet Laboratories Pvt Ltd has been
merged with Ortin. Vineet Laboratories is an established Drug
Intermediates manufacturing unit, majorly involved in the preparations
of intermediates for ANTI-RETRO VIRALS and LIPID LOWERING AGENTS which
is located in Choutuppal, Nalgonda District. The manufacturing unit is a
complex of Production Blocks, Quality Control, R & D and Quality
Assurance. The production blocks are well equipped with multipurpose SS
and GLASS-LINED REACTORS.
Ortin's Drug API Intermediates manufacturing unit has been
certified as an ISO 9001: 2008 company by Det Norske VERITAS, The
Netherlands for its quality systems management which shows the quality
conscious to deliver best quality products.
Ortin's Formulations unit has been certified as a WHO - GMP
certified company and an ISO 9001: 2008 Company by the Internationally
Recognized Quality Management Certification Body, the BMQR &
Accredited by AIAO-BAR, USA in pursuance of its focus towards Quality
with its Policy to enhance customer satisfaction by providing Quality
Pharmaceutical Formulations at optimum cost and maintain profitability
through continual improvement of Quality Management Sytems and cGMP.
Ortin is marketing its formulations all over India and its
products have been well accepted by the medical profession. Ortin is
honored as a registered Supplier of Drugs & Medicines with the most
reputed Central, State & Quasi-Government Organizations &
Institutions of our Country.
ORTIN is capable of producing 100 million tablets, 100
million capsules ,5 million dry powder bottles and 50,000 Lts Liquid
orals per month at its Formulation Unit.
List of product profile given on website. Company is having
vast product profile as well as working as merchant exporting trader.
Ortin, supply of pharmaceutical formulations comprising
tablets, capsules, liquid orals, ointments, injections, sterile dry
powder injections , liquid injections, ear drops, nasal drops, eye
drops, pharmaceutical veterinary tablets, dry syrups, liquid orals,
tablets, capsules, sterile powder.
Global presence:
Ortin's formulation unit is a WHO GMP and ISO 9001:2008
certified company. Ortin is already registered with NDA, UGANDA & MOH,
Srilanka and registration is under process in KENYA, TANZANIA, NIZERIA,
GHANA, SOUTH EAST ASIAN & CIS countries for our formulations. It is also manufacturing for different importers to market their products
in Russia, Ukraine, Kajakistan, South America etc.
Outlook:
Promoter holding 35% stake and company posted 40 cr top
line and 0.66 cr bottom line in latest 9 month ended 2016-17. Company
total market cap is equal to nine months sales. It is always safe and
best bet from pharma that sales to market cap ratio seems difficult to
find 1:1
Expecting good qtr result in coming time as company is working well which will turn fortune in near time. Stock trading both NSE and BSE @ 23.5
Disc: I am shareholder of the company.
NOTE : THE ABOVE IS NOT A RESEARCH REPORT NOR A RECOMMENDATION BUT INFORMATION AS AVAILABLE ON PUBLIC DOMAIN.
Registration status with SEBI: I am not registered with
SEBI under the (Research Analyst) regulations 2014 and as per
clarifications provided by SEBI: “Any person who makes recommendation or
offers an opinion concerning securities or public offers only through
public media is not required to obtain registration as research analyst
under RA Regulations”
No comments:
Post a Comment